Advances on immune-related adverse events associated with immune checkpoint inhibitors / 医学前沿
Frontiers of Medicine
;
(4): 33-42, 2021.
Article
Dans Anglais
| WPRIM
| ID: wpr-880945
ABSTRACT
Immunotherapy has recently led to a paradigm shift in cancer therapy, in which immune checkpoint inhibitors (ICIs) are the most successful agents approved for multiple advanced malignancies. However, given the nature of the non-specific activation of effector T cells, ICIs are remarkably associated with a substantial risk of immune-related adverse events (irAEs) in almost all organs or systems. Up to 90% of patients who received ICIs combination therapy experienced irAEs, of which majority were low-grade toxicity. Cytotoxic lymphocyte antigen-4 and programmed cell death protein-1/programmed cell death ligand 1 inhibitors usually display distinct features of irAEs. In this review, the mechanisms of action of ICIs and how they may cause irAEs are described. Some unsolved challenges, however really engrossing issues, such as the association between irAEs and cancer treatment response, tumor response to irAEs therapy, and ICIs in challenging populations, are comprehensively summarized.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Inhibiteurs de points de contrôle immunitaires
/
Immunothérapie
/
Tumeurs
/
Antinéoplasiques
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Frontiers of Medicine
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS